Rapport Therapeutics, Inc. (RAPP)
NASDAQ · Manufacturing · Pharmaceutical preparations
RAPP price, last 12 months
Key stats
- Previous close
- $33.83
- Open
- $33.80
- Day range
- $33.05 – $34.89
- 52-week range
- $23.75 – $52.93
- Volume
- 621.2K
- Avg volume (20 days)
- 447.7K
- Market cap
- $1.6B
Performance
Technicals and fundamentals
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.6B